CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Ava Inc., 2026-04-14
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: FDA issued a Warning Letter to Ava Inc. on 2026-04-14 citing: CGMP/Finished Pharmaceuticals/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026
Argus analysis
Ava Inc. (MARCS-CMS 721180, FEI 3008736380) received an FDA Warning Letter dated April 14, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/Finished Pharmaceuticals/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 5, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Ava Inc. MARCS-CMS 721180 — April 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL WITH READ RECEIPT Reference #: 320-26-64 Product: Drugs Recipient: Recipient Name Dr. Ram P. Chakroborty Recipient Title President & Chief Executive Officer Ava Inc. 7051 S. Adams St. Willowbrook , IL 60527-7592 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-64 April 14, 2026 Dear Dr. Ram P. Chakroborty: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Ava Inc., FEI 3008736380, at 7051 S. Adams St., Willowbrook, IL, from October 6 to October 21, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211), and significant deviations from CGMP for active pharmaceutical ingredients (APIs). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drugs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your November 12, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations and deviations including, but not limited to, the following. Finished Drug CGMP Violations 1. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)). Your firm lacked adequate system security and access controls over your laboratory equipment used to test drug products prior to release. For example, your firm utilized a common username and password to access high performance liquid chromatography (HPLC) equipment used for impurity testing of drug products. Additionally, analysts had administrator privileges to modify and delete data. Our investigators also found multiple deleted gas chromatography (GC) analytical sequences in the recycle bin, including sequences used for system suitability and stability analysis. In your response, you state your employee violated your procedure and training by deleting sequence files without informing the supervisor or quality assurance (QA). You also state a software update allowed users to bypass “User-Security Access Restrictions” and that you have disabled the automatic software update function. You also state that you have implemented security parameters to enhance access controls to electronic data files. Your response is inadequate. You do not provide adequate details of management oversight to ensure effectiveness of the corrective actions implemented. You…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Ava Inc.?
- FDA issued the letter (MARCS-CMS 721180) on 2026-04-14 and posted it publicly on fda.gov on 2026-05-05.
- Is the FDA warning letter to Ava Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ava-inc-721180-04142026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Ava Inc., 2026-04-14. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-ava-inc-2026-04-14-cgmp
"CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Ava Inc., 2026-04-14." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-ava-inc-2026-04-14-cgmp.
Argus HQ Research. "CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Ava Inc., 2026-04-14." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-ava-inc-2026-04-14-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_ava_inc_2026_04_14_cgmp_2026,
title = {CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Ava Inc., 2026-04-14},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-ava-inc-2026-04-14-cgmp},
note = {Accessed: July 13, 2026}
}